Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Progressive Encephalomyelitis with Rigidity Responsive to Plasmapheresis and Immunosuppression
Ann Neurol 40:451-453, Fogan,L., 1996
Clinical Presentation, Investigation Findings, and Outcomes of IgG4-Related Pachymeningitis,A Systematic Review
JAMA Neurol 82:193-199, Terrim,S.,et al, 2025
Immune Checkpoint Inhibitor-Related Myositis and Myocarditis in Patients with Cancer
Neurol 91:e985-e994, Touat, M.,et al, 2018
International Consensus Guidance for Management of Myasthenia Gravis
Neurol 87:419-425, Sanders, D.B.,et al, 2016
Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011
Whipples Disease
NEJM 356:55-66, Fenollar,F.,et al, 2007
Practice Parameter:Immunotherapy for Guillain-Barre Syndrome, Report of the Quality Standards Subcommittee of the American Academy of Neurology
Neurol 61:736-740, Hughes,R.A.C.,et al, 2003
Disease Modifying Therapies in Multiple Sclerosis
Neurol 58:169-178, Goodin,D.S.,et al, 2002
Severe Neurologic Complications After Hematopoietic Stem Cell Transplantation in Children
Neurol 59:1895-1904,E13, Farci,M.,et al, 2002
Reversible Tacrolimus-Induced Neurotoxicity Isolated to the Brain Stem
AJNR 21:1251-1254, Oliverio,P.J. et al, 2000
Treatment of Inflammatory Myopathies
Muscle & Nerve 20:651-664997., Mastaglia,F.L.,et al, 1997
Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994
A Referendum on Clinical Trial Research in Multiple Sclerosis:Opinion of Jekyll Island Workshop
Neurol 39:977-981, Noseworthy,J.H.,et al, 1989
Immunological Treatment for Multiple Sclerosis
Editorial, Lancet 1:699-7011989., , 1989
Immunotherapy of Multiple Sclerosis
Ann Neurol 23:211-223, Weiner,H.L.&Hafler,D.A., 1988
Polymyositis & Dermatomyositis
NEJM 292:344, 1975, 292:403975., Bohan,A.,et al, 1975